LENZ Therapeutics (LENZ) Shares Outstanding (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Shares Outstanding (Entity) of $31.4 million for Q1 2026, up 13.84% year-over-year from $27.5 million in Q1 2025, and little changed quarter-over-quarter from $31.3 million in Q4 2025.
LENZ Therapeutics (LENZ) Shares Outstanding (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Shares Outstanding (Entity) for 7 consecutive years, with $31.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 13.84% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at $31.4 million (up 13.84% YoY), while the FY2025 annual figure was $31.3 million, up 47.29% from the prior year.
- Shares Outstanding (Entity) steadied at $31.4 million in Q1 2026 per LENZ's latest filing, from $31.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $31.4 million in Q1 2026 and bottomed at $4.7 million in Q1 2024.
- Historically, Shares Outstanding (Entity) has averaged $17.2 million across 5 years, with a median of $8.3 million in 2022.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 1044.31% — and 2024, when it tumbled 43.26%.
- LENZ Therapeutics' Shares Outstanding (Entity) stood at $8.3 million in 2022, then slipped by 2.07% to $8.1 million in 2023, then surged by 161.27% to $21.3 million in 2024, then surged by 47.29% to $31.3 million in 2025, then increased by 0.03% to $31.4 million in 2026.
- Business Quant data shows LENZ's Shares Outstanding (Entity) at $31.4 million in Q1 2026, $31.3 million in Q4 2025, and $28.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 31.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.37 Mn |
| Mar 31, 2026 | 31.35 Mn |
| Dec 31, 2025 | 28.81 Mn |
| Sep 30, 2025 | 28.54 Mn |
| Jun 30, 2025 | 28.08 Mn |
| Mar 31, 2025 | 27.53 Mn |
| Dec 31, 2024 | 21.28 Mn |
| Sep 30, 2024 | 27.17 Mn |
| Jun 30, 2024 | 25.61 Mn |
| Mar 31, 2024 | 4.72 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 8.18 Mn |
| Jun 30, 2023 | 8.11 Mn |
| Mar 31, 2023 | 7.98 Mn |
| Dec 31, 2022 | 7.84 Mn |
| Sep 30, 2022 | 7.89 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 4.13 Mn |
| Sep 30, 2021 | 7.54 Mn |